← Back to Search

Cancer Vaccine

Dendritic Cell Vaccine for Brain Cancer

Phase 2

Waitlist Available

Research Sponsored by Jonsson Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must be 18 years or older and able to read and understand the informed consent document

Patients with newly diagnosed or recurrent glioma of WHO Grade III or IV (anaplastic astrocytoma, anaplastic astro-oligodendroglioma, or glioblastoma) eligible

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial is testing which combination of immunotherapy vaccines is most effective in patients with malignant glioma, a type of brain cancer. Dendritic cells, which present cell identifiers to the immune system, are isolated from the subject's blood and pulsed with tumor lysate, a combination that is hoped will stimulate the immune system to recognize and destroy the patient's brain tumor. The pulsed dendritic cells are then injected back into the patient, with or without adjuvant imiquimod or poly ICLC.

Who is the study for?

This trial is for adults with malignant glioma (brain tumors) who've had surgery at UCLA. They must have a certain level of physical ability (KPS > 60), be able to consent, and not have infections, severe medical conditions, organ transplants, other active cancers, or immune/autoimmune diseases. Women must not be pregnant and should use contraception.Check my eligibility

What is being tested?

The study tests different immunotherapy vaccines on brain tumor patients. It uses the patient's own dendritic cells combined with their tumor tissue to stimulate the immune system against the tumor. Some treatments include adjuvants like imiquimod or poly ICLC to boost effectiveness.See study design

What are the potential side effects?

While previous studies suggest safety, potential side effects may include reactions at injection sites, flu-like symptoms due to immune response activation, and possible worsening of autoimmune conditions if present.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 or older and can understand the consent form.

Select...

My brain tumor is classified as Grade III or IV glioma.

Select...

I had surgery at UCLA and agreed to donate my tumor for research.

Select...

My surgery confirmed I have a high-grade malignant brain tumor.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Most effective combination of DC vaccine components

Secondary outcome measures

Time to tumor progression and overall survival

Trial Design

3Treatment groups

Experimental Treatment

Group I: Tumor-lysate pulsed DC vaccination +adjuvant polyICLC.Experimental Treatment1 Intervention

Cohort #3 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant poly ICLC (TLR3 agonist).

Group II: Tumor lysate-pulsed DC vaccination+0.2% resiquimod.Experimental Treatment1 Intervention

Cohort #2 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant 0.2% resiquimod.

Group III: Tumor Lysate-pulsed DC vaccinationExperimental Treatment1 Intervention

Cohort #1 will receive autologous tumor lysate-pulsed DC vaccination together with a placebo cream or intramuscular injection of saline.

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor

359 Previous Clinical Trials

26,015 Total Patients Enrolled

Media Library

Autologous tumor lysate-pulsed DC vaccination (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT01204684 — Phase 2

Brain Tumor Research Study Groups: Tumor-lysate pulsed DC vaccination +adjuvant polyICLC., Tumor Lysate-pulsed DC vaccination, Tumor lysate-pulsed DC vaccination+0.2% resiquimod.

Brain Tumor Clinical Trial 2023: Autologous tumor lysate-pulsed DC vaccination Highlights & Side Effects. Trial Name: NCT01204684 — Phase 2

Autologous tumor lysate-pulsed DC vaccination (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01204684 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the sample size for this clinical trial?

"This particular study has completed recruitment and is no longer looking for patients. The trial was initially posted on October 8th, 2010, with the most recent update being on July 18th, 2022. If you are interested in other studies, there are 744 clinical trials currently underway for patients with glioma and 1 autologous tumor lysate-pulsed DC vaccination study that is actively recruiting participants."

Answered by AI

Are patients still being enrolled in this research project?

"Unfortunately, this trial is no longer recruiting patients. The study was first posted on October 8th, 2010 and was updated for the last time on July 18th, 2022. However, there are still 744 trials searching for patients with glioma and 1 autologous tumor lysate-pulsed DC vaccination study that are currently open to enrolment."

Answered by AI

Does age preclude patients from participating in this research?

"This trial requires that all participants be between 18-70 years old, as specified in the eligibility criteria."

Answered by AI

Is it permissible to give patients autologous tumor lysate-pulsed DC vaccinations?

"Autologous tumor lysate-pulsed DC vaccination is a Phase 2 trial, which means that while there is some safety data supporting its use, efficacy has yet to be proven."

Answered by AI

Are there other clinical trials that have used autologous tumor lysate-pulsed DC vaccination?

"Currently, there is 1 clinical trial testing autologous tumor lysate-pulsed DC vaccination. No trials have reached Phase 3 yet. Most of the locations for this study are in Los Angeles, California; however, there is 1 other site conducting these tests."

Answered by AI

Are there any specific requirements for participants in this clinical trial?

"This trial is recruiting 60 participants, between the ages of 18 and 70 who have glioma. It is important that patients also meet the following criteria: Patients must have had surgical resection at UCLA (University of California, Los Angeles), for which a separate informed consent was signed for the collection of their tumor prior to surgery., Patients with newly diagnosed or recurrent glioma of WHO Grade III or IV {anaplastic astrocytoma (AA), anaplastic astro-oligodendroglioma (AO), or glioblastoma (GBM)} will be eligible for this protocol"

Answered by AI